Ziopharm Oncology Inc. (NASDAQ:ZIOP) fell 3.2% on Friday . The stock traded as low as $5.75 and last traded at $5.76, with a volume of 715,003 shares traded. The stock had previously closed at $5.95.

Several brokerages have weighed in on ZIOP. Mizuho reiterated a “neutral” rating and issued a $5.00 target price (down from $7.00) on shares of Ziopharm Oncology in a report on Monday, July 18th. Griffin Securities restated a “buy” rating and set a $21.00 price objective on shares of Ziopharm Oncology in a research note on Tuesday, June 7th. Wells Fargo & Co. upgraded Ziopharm Oncology from an “underperform” rating to a “market perform” rating in a research note on Wednesday, August 10th. Raymond James Financial Inc. began coverage on Ziopharm Oncology in a research note on Thursday, June 2nd. They set a “market perform” rating for the company. Finally, Vetr upgraded Ziopharm Oncology from a “buy” rating to a “strong-buy” rating and set a $9.76 price objective for the company in a research note on Monday, April 25th. Four investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. Ziopharm Oncology currently has an average rating of “Buy” and a consensus target price of $9.75.

The stock’s 50-day moving average is $5.29 and its 200 day moving average is $6.75. The firm’s market cap is $759.49 million.

Ziopharm Oncology (NASDAQ:ZIOP) last posted its earnings results on Tuesday, August 9th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.90. The business earned $1.70 million during the quarter, compared to the consensus estimate of $1.52 million. The firm’s revenue was up 525.0% compared to the same quarter last year. During the same period last year, the business posted ($0.11) earnings per share. On average, equities research analysts predict that Ziopharm Oncology Inc. will post ($1.34) earnings per share for the current fiscal year.

Other large investors have bought and sold shares of the company. Swiss National Bank boosted its stake in Ziopharm Oncology by 2.2% in the fourth quarter. Swiss National Bank now owns 159,220 shares of the biotechnology company’s stock valued at $1,323,000 after buying an additional 3,500 shares during the period. California Public Employees Retirement System boosted its stake in Ziopharm Oncology by 567.2% in the fourth quarter. California Public Employees Retirement System now owns 307,366 shares of the biotechnology company’s stock valued at $2,554,000 after buying an additional 261,300 shares during the period. Finally, Morgan Stanley boosted its stake in Ziopharm Oncology by 5.1% in the fourth quarter. Morgan Stanley now owns 1,618,205 shares of the biotechnology company’s stock valued at $13,447,000 after buying an additional 78,583 shares during the period.

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.